Browse the evidence

Every 5 kg of weight loss from anti-obesity treatment reduces the risk of myocardial infarction, stroke, and heart failure.

Losing just 5 kg (about 11 lbs) through anti-obesity treatments can significantly lower your risk of heart attack, stroke, and heart failure. This highlights the importance of achieving even modest weight loss for long-term cardiovascular health. Work with your healthcare provider to find a safe and effective weight management strategy.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and placebo in patients with obesity.

Tirzepatide (5-15 mg weekly) is a potent option for obesity, achieving up to 21% weight loss in trials. It is a dual GIP/GLP-1 agonist. Consider it if semaglutide is insufficient or not tolerated, provided cost and access allow.

Tirzepatide demonstrates superior weight loss efficacy compared to Semaglutide, achieving an average weight loss of -20.9% at the highest dose (15 mg) in obese patients without type 2 diabetes.

If you are struggling to lose weight with Semaglutide, ask your doctor about Tirzepatide. Clinical trials show it can lead to greater weight loss (around 21%) compared to Semaglutide (around 14%) in obese patients without diabetes. However, be aware that it may be more expensive and less likely to be covered by insurance.

Weight loss of 7-10% is required to resolve steatohepatitis (MASH) and regress fibrosis, whereas 5% loss primarily improves steatosis.

To reverse liver inflammation, aim for a 7-10% total body weight loss through diet and exercise. Losing 5% helps reduce liver fat, but hitting the higher threshold is necessary to fix the actual liver damage (inflammation). Combine caloric restriction with both aerobic and resistance training to preserve muscle mass.

The physiological mechanism of diabetes remission via weight loss involves the reduction of ectopic fat in the liver and pancreas, which restores beta-cell function and insulin sensitivity.

N/A (Mechanistic explanation).

GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce major adverse cardiovascular events (MACE) and heart failure hospitalizations in patients with type 2 diabetes, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about GLP-1 RAs or SGLT2is. These drugs protect your heart and kidneys, not just your blood sugar. They are often preferred over older medications like metformin if you have these risks.

Tirzepatide (5-15 mg once weekly) significantly reduces HbA1c (by 1.5-2.5%) and body weight (by 15-25%) in patients with type 2 diabetes and obesity, outperforming standard therapies like semaglutide and insulin.

Tirzepatide is a once-weekly injection approved for T2DM and obesity. It works by mimicking hormones that regulate blood sugar and appetite. Clinical trials show it lowers HbA1c by up to 2.5% and causes significant weight loss (15-25%). It is more effective than semaglutide and insulin for these metrics. Common side effects are gastrointestinal (nausea, diarrhea) but often improve over time. Weight regain is common if the drug is stopped, suggesting long-term use may be necessary for sustained results.

Tirzepatide (dual GIP/GLP-1 agonist) produces significantly greater weight loss and waist circumference reduction than semaglutide (selective GLP-1 agonist) in adults with obesity without diabetes.

If your primary goal is maximum weight loss and you do not have diabetes, tirzepatide (15mg weekly) is clinically superior to semaglutide (2.4mg weekly). While both are effective, tirzepatide yields significantly greater fat loss and waist reduction. Be aware that while tirzepatide may have better GI tolerability, it still carries class-specific risks.

Discontinuation of incretin-based therapies (GLP-1/GIP agonists) consistently leads to rapid and clinically meaningful weight regain, typically recovering two-thirds of lost weight within one year, alongside the reversal of cardiometabolic improvements.

If you stop taking incretin-based weight loss medication, you will likely regain about two-thirds of the weight you lost within a year. This is not a failure of willpower but a biological response to the loss of the drug's hormonal effects. To maintain your weight loss, you likely need to continue the medication long-term or use very aggressive, sustained lifestyle interventions, though even those are often insufficient to prevent significant regain.

GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant, clinically meaningful weight loss (10-21%) and reduce the incidence of type 2 diabetes in adults with overweight or obesity, with effects rivaling metabolic surgery.

GLP-1 and dual agonists are highly effective for significant weight loss (up to 21%) and diabetes prevention in adults with obesity. They work by targeting hormonal pathways to reduce appetite and improve insulin sensitivity. While effective, they require long-term use to maintain benefits, as stopping leads to significant weight regain. Side effects like nausea and diarrhea are common but manageable, and the choice of agent depends on individual tolerance and specific health goals.

mTORC1 is the central integrator of anabolic signals from both resistance exercise and dietary protein, mediating muscle protein synthesis and hypertrophy.

Understanding mTORC1 is important for researchers but has limited direct practical application for the average person. Focus on the external drivers: lift weights and eat enough protein.

Intensive lifestyle interventions (diet, physical activity, weight management) reduce the risk of progression from prediabetes to type 2 diabetes by 42-58% and improve long-term cardiovascular outcomes.

Start with a 6-month intensive lifestyle program focusing on losing 5-10% of your body weight and getting at least 150 minutes of moderate exercise (like brisk walking) per week. Combine this with dietary changes and smoking cessation if applicable. Follow up with your healthcare provider after 3 months to assess progress and adjust your plan. This is the most effective first step to prevent progression to type 2 diabetes.

Metformin reduces the risk of progression from prediabetes to type 2 diabetes by 31% and is recommended for specific high-risk subgroups (age 25-59, BMI ≥35, FPG ≥6.1 mmol/L, or history of gestational diabetes).

If lifestyle changes alone are not enough, your doctor may prescribe metformin. It is typically started at a low dose (500 mg) and increased to 1,500 mg daily to minimize stomach issues. Use the extended-release version if possible. Monitor your blood sugar every 6 months. This is particularly recommended if you are younger, have a higher BMI, or have a history of gestational diabetes.

Second-generation obesity management medications (semaglutide and tirzepatide) produce 15-20% body weight loss, significantly exceeding the 5-10% typically achieved by lifestyle interventions alone.

Second-generation obesity medications like semaglutide and tirzepatide are significantly more effective for weight loss than lifestyle changes alone, achieving 15-20% body weight reduction. They work by targeting hormonal pathways that regulate appetite and metabolism, addressing the biological drivers of obesity rather than relying solely on willpower.

Discontinuation of second-generation OMMs leads to significant weight regain, highlighting the chronic nature of obesity and the need for long-term management or intensive lifestyle support upon discontinuation.

Stopping OMMs typically leads to significant weight regain. If you choose to discontinue, work with your healthcare provider to intensify lifestyle interventions, including dietary strategies and physical activity, to help maintain your weight loss.

Once-weekly subcutaneous semaglutide 2.4 mg produces significant weight loss in adults with overweight or obesity, with efficacy largely independent of baseline characteristics such as age, race, BMI, and glycemic status, though females and those with lower baseline body weight experience greater magnitude of loss.

If you have obesity or overweight, once-weekly semaglutide (2.4 mg) is a highly effective treatment for weight loss, regardless of your age, race, or starting weight. However, be aware that women and those with a lower starting body weight tend to lose more weight than men or those with a higher starting body weight. This treatment is used alongside lifestyle changes.

4:3 intermittent fasting (80% energy restriction on 3 nonconsecutive days/week) produces modestly greater weight loss than matched daily caloric restriction over 12 months when both are delivered within a high-intensity, comprehensive behavioral weight loss program.

If you struggle with daily calorie counting, try 4:3 intermittent fasting: restrict calories by 80% on 3 nonconsecutive days a week and eat normally on the other 4. This approach led to slightly better weight loss than daily restriction in a 12-month study, likely because it is easier to stick to. Combine this with regular exercise and behavioral support for best results.

Adherence to a low-carbohydrate diet (LCD) results in significantly greater reductions in body mass index (BMI), total body weight, and body fat percentage compared to a low-fat diet (LFD).

If you are trying to lose weight, a low-carbohydrate diet (30-130g carbs/day) is likely to produce slightly better results in BMI, total weight, and body fat percentage than a low-fat diet. This holds true across various populations, including those with type 2 diabetes or metabolic syndrome. Note that the absolute difference in fat mass (kg) and waist circumference was not significantly different between the two diets in the overall analysis.

Tirzepatide (5-15 mg weekly) produces superior weight loss (10.7-20.9%) compared to placebo in adults with obesity (BMI ≥30 or ≥27 with comorbidities) via dual GIP/GLP-1 receptor agonism.

Tirzepatide is a once-weekly injection that significantly reduces body weight (up to 20%+) in obese adults. It works by mimicking gut hormones to suppress appetite and slow digestion. Start with the lowest dose and increase gradually to minimize stomach upset. Combine with a 500-calorie daily deficit and 150 minutes of weekly exercise for best results.

Once-weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces body weight, BMI, and waist circumference in adults with obesity or overweight compared to placebo, with effects demonstrating a dose-response relationship.

For adults with obesity or overweight, once-weekly semaglutide (titrated up to 2.4 mg) combined with lifestyle changes is a highly effective medical intervention for significant weight loss, outperforming lifestyle changes alone. While gastrointestinal side effects like nausea are common, they are usually manageable and do not typically lead to stopping treatment.

Once-weekly semaglutide improves cardiometabolic markers including HbA1c, fasting plasma glucose, blood pressure, and lipid profiles in overweight/obese patients, independent of or alongside weight loss.

Beyond weight loss, semaglutide helps improve blood sugar control (HbA1c), blood pressure, and lipid profiles in overweight/obese individuals, offering broader cardiovascular protection.

Cognitive-behavioral therapy for insomnia (CBT-I) is the first-line treatment for insomnia disorder, with hypnotics recommended only for short-term use when CBT-I is unavailable or ineffective.

If you have chronic insomnia, seek Cognitive-Behavioral Therapy for Insomnia (CBT-I) as your primary treatment. It is the gold standard recommended by all major medical guidelines. Use sleep medications only as a short-term bridge if CBT-I is not accessible, not as a long-term solution.

Tirzepatide (5, 10, and 15 mg once-weekly) provides superior glycemic control (HbA1c reduction) and greater body weight loss compared to placebo, GLP-1 receptor agonists, and basal insulin in adults with type 2 diabetes.

Tirzepatide is a once-weekly injection that lowers blood sugar and helps with weight loss more effectively than existing GLP-1 drugs (like semaglutide) and basal insulin. It works by mimicking two gut hormones (GIP and GLP-1). While it is very effective, it can cause stomach issues like nausea and diarrhea, which might lead some people to stop taking it, especially at higher doses. It does not increase the risk of low blood sugar (hypoglycemia) on its own.

Achieving 8.75 marginal MET-hours per week of non-occupational physical activity (equivalent to 150 minutes/week of moderate-to-vigorous aerobic activity) significantly reduces the risk of all-cause mortality, cardiovascular disease, and total cancer incidence compared to inactivity.

To significantly lower your risk of early death and heart disease, aim for 150 minutes per week of moderate-to-vigorous activity (like brisk walking) outside of work. This is the most impactful change you can make if you are currently inactive. Benefits are largest when moving from zero activity to this level.